NAC Attack A Phase III Multicenter Randomized Parallel

Recruiting

99 years or below

All

1 Location

Brief description of study

The objective of the study will be to evaluate the efficacy and safety of oral N-acetylcysteine (NAC) in patients with retinitis pigmentosa (RP). The study is a multi-center, randomized, placebo-controlled study where adult patients diagnosed with RP will be asked to take 1800mg NAC bid or a placebo. Patients will be followed for 45 months with a series of clinic visits, tele-visits and phone calls, and safety and efficacy will be assessed using tests to measure visual function and structure.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 14 Jun 2023. Study ID: 853552

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

NAC Attack A Phase III Multicenter Randomized Parallel Double Masked Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients with Retinitis Pigmentosa

Brief description of study

Eligibility of study

Find a site

Interested in the study